

JOURNAL OF HEPATOLOGY

VOLUME 53, ISSUE 4, PAGES 591–788

FOCUS

591 **Focus.** *D. Shouval*

EDITORIALS

593 **Prognosis indicator in acute liver failure: Is there a place for cell death markers?** *D. Samuel, P. Ichai*

596 **Exploiting liver immunity for the prevention of hepatic metastases.** *L. Rivoltini, V. Mazzaferro*

RESEARCH ARTICLES

Viral Hepatitis

599 **A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals.** *E.J. Gowans, S. Roberts, K. Jones, I. Dinatale, P.A. Latour, B. Chua, E.M.Y. Eriksson, R. Chin, S. Li, D.M. Wall, R.L. Sparrow, J. Moloney, M. Loudovaris, R. Ffrench, H.M. Prince, D. Hart, W. Zeng, J. Torresi, L.E. Brown, D.C. Jackson*

608 **The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection.** *K. Foerster, A. Helmy, Y. Zhu, R. Khattar, O.A. Adeyi, K.M. Wong, I. Shalev, D.A. Clark, P.-Y. Wong, E.J. Heathcote, M.J. Phillips, D.R. Grant, E.L. Renner, G.A. Levy, N. Selzner*

616 **Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.** *W.S.C. Cheng, S.K. Roberts, G. McCaughan, W. Sievert, M. Weltman, D. Crawford, W. Rawlinson, P.S. Marks, J. Thommes, B. Rizkalla, M. Yoshihara, G.J. Dore, on behalf of the CHARLOT Study Group*

Cirrhosis

624 **Measurement of hepatic vein pressure gradient in children with chronic liver diseases.** *R. Miraglia, A. Luca, L. Maruzzelli, M. Spada, S. Riva, S. Caruso, G. Maggiore, B. Gridelli, J. Bosch*

630 **Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive**

markers: Results of a multicenter, large-scale study. *G. Sebastiani, D. Tempesta, G. Fattovich, L. Castera, P. Halfon, M. Bourliere, F. Noventa, P. Angeli, A. Saggiaro, A. Alberti*

Liver Failure and Growth

639 **Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury.** *L.P. Bechmann, C. Jochum, P. Kocabayoglu, J.-P. Sowa, M. Kassalik, R.K. Gieseler, F. Saner, A. Paul, C. Trautwein, G. Gerken, A. Canbay*

648 **Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation.** *T. Kawasaki, S. Murata, K. Takahashi, R. Nozaki, Y. Ohshiro, N. Ikeda, S. Pak, A. Myronovych, K. Hisakura, K. Fukunaga, T. Oda, R. Sasaki, N. Ohkohchi*

655 **Early growth response-1 attenuates liver injury and promotes hepatoprotection after carbon tetrachloride exposure in mice.** *M.T. Pritchard, J.I. Cohen, S. Roychowdhury, B.T. Pratt, L.E. Nagy*

663 **Pancreatic Duodenal Homeobox-1 *de novo* expression drives cholangiocyte neuroendocrine-like transdifferentiation.** *M. Marzioni, S. Saccomanno, C. Candelaesi, C. Rychlicki, L. Agostinelli, K. Shanmukhappa, L. Trozzi, I. Pierantonelli, S.D. Minicis, A. Benedetti*

Cancer

671 **Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China.** *L. Xu, G. Qian, L. Tang, J. Su, J.-S. Wang*

677 **Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy.** *G.J. van der Bij, M. Bögels, M.A. Otten, S.J. Oosterling, P.J. Kuppen, S. Meijer, R.H.J. Beelen, M. van Egmond*

Molecular and Cell Biology

686 **TR β is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells.** *M.A. Kowalik, A. Perra, M. Pibiri, M.T. Cocco, J. Samarut, M. Plateroti, G.M. Ledda-Columbano, A. Columbano*

693 Hepatocytes express functional NOD1 and NOD2 receptors: A role for NOD1 in hepatocyte CC and CXCL chemokine production. M.J. Scott, C. Chen, Q. Sun, T.R. Billiar

702 Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J. Trebicka, M. Hennenberg, M. Odenthal, K. Shir, S. Klein, M. Granzow, A. Vogt, H.-P. Dienes, F. Lammert, J. Reichen, J. Heller, T. Sauerbruch

Genetic and Metabolic Diseases

713 Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. G. Targher, L. Bertolini, R. Padovani, S. Rodella, G. Zoppini, I. Pichiri, C. Sorgato, L. Zenari, E. Bonora

719 Hepatocellular ballooning in NASH. S. Caldwell, Y. Ikura, D. Dias, K. Isomoto, A. Yabu, C. Moskaluk, P. Pramoongjago, W. Simmons, H. Scroggs, N. Rosenbaum, T. Wilkinson, P. Toms, C.K. Argo, A.M.S. Al-Osaimi, J.A. Redick

724 Down-regulation of SREBP-1c is associated with the development of burned-out NASH. T. Nagaya, N. Tanaka, T. Suzuki, K. Sano, A. Horiuchi, M. Komatsu, T. Nakajima, T. Nishizawa, S. Joshita, T. Umemura, T. Ichijo, A. Matsumoto, K. Yoshizawa, J. Nakayama, E. Tanaka, T. Aoyama

732 In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease: Correlation with biochemical method and morphometry. E. Roldan-Valadez, R. Favila, M. Martínez-López, M. Uribe, C. Ríos, N. Méndez-Sánchez

REVIEWS

738 Induced pluripotent stem cells: A new era for hepatology. S. Asgari, B. Pournasr, G.H. Salekdeh, A. Ghodsizadeh, M. Ott, H. Baharvand

752 Hepatitis C virus infection: A “liaison a trois” amongst the virus, the host, and chronic low-level inflammation for human survival. V. Barnaba

POSITION PAPER

762 Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. R. de Franchis, On behalf of the Baveno V Faculty

SPECIAL SECTIONS

Frontiers in Liver Transplantation

769 Barriers to the successful treatment of liver disease by hepatocyte transplantation. K.A. Soltys, A. Soto-Gutiérrez, M. Nagaya, K.M. Baskin, M. Deutsch, R. Ito, B.L. Shneider, R. Squires, J. Vockley, C. Guha, J. Roy-Chowdhury, S.C. Strom, J.L. Platt, I.J. Fox

International Hepatology

775 Radiofrequency ablation for the treatment of HCC – Maybe much more than simple tumor destruction? T.F. Greten, F. Korangy

777 Building a bridge between obesity, inflammation and liver carcinogenesis. J.-C. Nault, J. Zucman-Rossi

CASE REPORT

780 HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus. J.P. Power, M. El Chaar, J. Temple, M. Thomas, D. Spillane, D. Candotti, J.P. Allain

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005. More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004; 351:1250–1251 and *New Engl J Med* 2005; 352:2437–2438.

Cover image taken from Trebicka *et al.* in this issue (page 710), Figure 8. Nuclei of apoptotic cells were FITC (green) labelled using TUNEL assay, while the cytoskeleton of myofibroblasts was stained by red immunofluorescence by means of Cy3-conjugated anti-alpha SMA antibodies (section of BDL with original magnification 100×).